VolitionRx (NYSE:VNRX) Now Covered by StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research note issued on Saturday. The firm set a “sell” rating on the stock.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $2.50 price target on shares of VolitionRx in a research note on Wednesday, March 27th.

VolitionRx Stock Up 1.4 %

Shares of VNRX opened at $0.89 on Friday. The firm has a market cap of $73.12 million, a price-to-earnings ratio of -1.75 and a beta of 1.26. The business’s 50 day moving average is $0.83 and its two-hundred day moving average is $0.85. VolitionRx has a 52-week low of $0.55 and a 52-week high of $2.09.

VolitionRx (NYSE:VNRX) last posted its quarterly earnings results on Monday, March 25th. The company reported ($0.11) earnings per share (EPS) for the quarter. The company had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.50 million. On average, equities analysts expect that VolitionRx will post -0.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On VolitionRx

An institutional investor recently bought a new position in VolitionRx stock. Silverberg Bernstein Capital Management LLC purchased a new position in VolitionRx Limited (NYSE:VNRX) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned about 0.19% of VolitionRx at the end of the most recent quarter. 8.09% of the stock is owned by institutional investors and hedge funds.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.